The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.<\/p>\n
Top 5 Upgrades:<\/b><\/p>\n JPMorgan upgraded IBM<\/b> (IBM)<\/a> to Overweight from Neutral with a price target of $291, up from $270. The firm cites its greater confidence in a second half of 2026 software acceleration following an analysis of IBM’s software business for the upgrade.<\/p>\n<\/li>\n Wolfe Research upgraded Target<\/b> (TGT)<\/a> to Outperform from Peer Perform with a $162 price target. The analyst also named the stock a top pick into year-end. Target is seeing improved execution as the new management team shakes up the status quo, the analyst tells investors in a research note.<\/p>\n<\/li>\n Piper Sandler upgraded Synopsys<\/b> (SNPS)<\/a> to Overweight from Neutral with a price target of $550, up from $450. The firm sees a faster than-expected recovery for the company’s intellectual property business.<\/p>\n<\/li>\n Morgan Stanley upgraded Qiagen<\/b> (QGEN)<\/a> to Overweight from Equal Weight with a price target of $42, up from $40. The firm says signs of a growth inflection coupled with sector underperformance in 2026 provides opportunities in the European medical technology space.<\/p>\n<\/li>\n Morgan Stanley upgraded CDW<\/b> (CDW)<\/a> to Overweight from Equal Weight with a price target of $170, up from $142. The firm says enterprise server demand is “proving far more inelastic than expected” due to compute shortages, refresh activity, and growing AI-related infrastructure<\/p>\n<\/li>\n<\/ul>\n Top 5 Downgrades:<\/b><\/p>\n Evercore ISI downgraded Nike<\/b> (NKE)<\/a> to In Line from Outperform with a price target of $46, down from $57. About two years into the turnaround, the firm’s checks are still picking up unexpected new resets lower in the wholesale channel, “minimal needle-moving innovation” in the pipeline into calendar 2027, and near-term execution issues, including World Cup delivery issues, the analyst tells investors.<\/p>\n<\/li>\n Wolfe Research downgraded Home Depot<\/b> (HD)<\/a> to Peer Perform from Outperform without a price target. The firm believes the stock “remains in limbo” as the lock-in effect and a strategy shift towards the large pro segment raise questions about Home Depot’s earnings power.<\/p>\n<\/li>\n Wells Fargo downgraded Ross Stores<\/b> (ROST)<\/a> to Equal Weight from Overweight with an unchanged price target of $245. The firm cites valuation for the downgrade following the stock’s re-rating.<\/p>\n<\/li>\n KeyBanc downgraded Primoris <\/b>(PRIM)<\/a> to Sector Weight from Overweight without a price target. The company is “tough to defend” after another guidance cut, its fourth negative update in a row, the analyst tells investors in a research note.<\/p>\n<\/li>\n\n
\n